What treatments actually work?
Medication, therapy, and everything in between — what the evidence says, and what it doesn’t.
about 3 min
Quick answer 30 sec
Three things have real evidence in adults: medication (stimulants such as methylphenidate and amphetamines; non-stimulants such as atomoxetine), psychological treatment adapted to ADHD (mainly CBT focused on organisation, planning and avoidance), and understanding what ADHD is (psychoeducation). Medication has the strongest short-term evidence on symptoms. Nothing has decades-long randomised evidence. The decision is made with a clinician who knows you.
What this can feel like
Lived experience
You’ve read ten contradictory opinions on medication and feel less able to decide than before.
You tried a tip from a video, it worked for three days, and you concluded you were the problem.
Someone close to you thinks treatment is cheating, or dangerous, or both.
You want to know what works — not what sells.
A composite of what people describe — not a checklist, not a test. ADHD, or just being human?
What’s happening 2–3 min
Medication. In network meta-analyses pooling dozens of randomised trials, stimulants reduce core symptoms in adults over weeks, with amphetamines and methylphenidate showing the largest effects; atomoxetine also works, with a smaller effect. Trials are short (mostly 6–12 weeks). Common side effects: reduced appetite, trouble sleeping, a rise in heart rate and blood pressure — which is why monitoring is part of guidelines.
Psychological treatment. CBT adapted to adult ADHD — organisation systems, planning, breaking tasks down, managing distraction, recognising avoidance — improves symptoms and functioning in the short term across 32 studies, with moderate effects, smaller when the rater does not know who got therapy. It is often tested in people already on medication. A randomised trial of a self-guided digital programme also found benefits — the format of Amorce.
Long term. No randomised trial follows people for decades. Large register studies suggest lower mortality with treatment, mostly from accidents and other unnatural causes, and a small rise in cardiovascular risk per year of use. These are observational findings: people who take treatment differ from those who don’t, so the numbers are informative, not proof.
Everything else. Mindfulness-based programmes show small-to-moderate effects in lower-quality studies. Coaching is widely offered and little tested. Working-memory training, supplements, neurofeedback for consumers, “dopamine detox”: no convincing evidence. Exercise helps attention in the hour after a session, in small studies.
How sure are we?
Strong, replicated evidence — usually meta-analyses or international consensus. Unlikely to change much. What these labels mean Stimulants (methylphenidate, amphetamines) reduce core ADHD symptoms in adults in the short term; atomoxetine too, with a smaller effect.
Cortese et al. 2018 +1
- Meta-analysis Cortese S, Adamo N, Del Giovane C, et al. (2018). Comparative efficacy and tolerability of medications for ADHD in children, adolescents, and adults: a systematic review and network meta-analysis. The Lancet Psychiatry, 5(9), 727–738. Open source ↗133 double-blind randomised trials; short-term outcomes (about 12 weeks).
- Meta-analysis Ostinelli EG, et al. (senior author: Cortese S) (2025). Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: a systematic review and component network meta-analysis. The Lancet Psychiatry. Open source ↗Adults only. Short-term symptom benefits for stimulants and atomoxetine; little evidence on quality of life or long-term outcomes.
Strong, replicated evidence — usually meta-analyses or international consensus. Unlikely to change much. What these labels mean CBT adapted to adult ADHD improves symptoms and functioning in the short term (moderate effects; smaller on blinded ratings and against active controls).
Knouse et al. 2017 +4
- Meta-analysis Knouse LE, Teller J, Brooks MA (2017). Meta-analysis of cognitive-behavioral treatments for adult ADHD. Journal of Consulting and Clinical Psychology, 85(7), 737–750. Open source ↗32 studies; moderate effects on symptoms and functioning versus control, smaller on blinded ratings.
- Meta-analysis See original article (network meta-analysis) (2024). Components of cognitive–behavioural therapy for mitigating core symptoms in attention-deficit hyperactivity disorder: a systematic review and network meta-analysis. BMJ Mental Health, 27, e301303. Open source ↗43 trials, 3,817 participants; organisational strategies were the component most associated with treatment response.
- Meta-analysis Yang X, Zhang L, Yu J, Wang M (2025). Short-term and long-term effect of non-pharmacotherapy for adults with ADHD: a systematic review and network meta-analysis. Frontiers in Psychiatry, 16, 1516878. Open source ↗37 RCTs, 2,289 adults; certainty of evidence low to very low; neurofeedback, working-memory training, tai chi and vitamins showed no benefit.
- Randomised trial Safren SA, Sprich S, Mimiaga MJ, et al. (2010). Cognitive behavioral therapy vs relaxation with educational support for medication-treated adults with ADHD and persistent symptoms: a randomized controlled trial. JAMA, 304(8), 875–880. Open source ↗86 adults already on medication; 12 weekly sessions.
- Randomised trial Solanto MV, Marks DJ, Wasserstein J, et al. (2010). Efficacy of meta-cognitive therapy for adult ADHD. American Journal of Psychiatry, 167(8), 958–968. Open source ↗88 adults; 12 weekly group sessions on time management, organisation and planning vs supportive therapy.
Promising and growing, but incomplete: several consistent studies, often small or without a meta-analysis. Could change. What these labels mean A self-guided digital CBT programme improved symptoms in one large randomised trial (337 adults, d = 0.85 at 3 months) — funded by its developer, not yet replicated.
attexis RCT 2025 +1
- Randomised trial See original article (2025). Effectiveness of attexis, a digital intervention based on cognitive behavioral therapy for adults with ADHD: a randomized controlled trial. medRxiv preprint (2025); Psychological Medicine (2026). Open source ↗337 adults; self-guided; d = 0.85 at 3 months, stable at 6; funded by the product’s developer.
- Randomised trial Antshel KM, McBride H, Knouse LE (2025). Bridging the gap: digital CBT for adults managing ADHD challenges. Journal of Attention Disorders. Open source ↗154 adults, 8 weeks, compared with a waitlist (which tends to overestimate effects).
Promising and growing, but incomplete: several consistent studies, often small or without a meta-analysis. Could change. What these labels mean In register studies, treatment is associated with lower all-cause mortality (about −19% over two years), mainly through fewer unnatural deaths.
Li et al. 2024
- Cohort / register study Li L, Zhu N, Zhang L, et al. (2024). ADHD pharmacotherapy and mortality in individuals with ADHD. JAMA, 331(10), 850–860. Open source ↗Swedish register, ~149,000 people; observational — lower all-cause mortality over two years with treatment, mainly from unnatural causes.
Promising and growing, but incomplete: several consistent studies, often small or without a meta-analysis. Could change. What these labels mean Long-term use is associated with a small rise in cardiovascular disease risk (about +4% per year), mostly hypertension and arterial disease.
Zhang et al. 2024
- Cohort / register study Zhang L, Li L, Andell P, et al. (2024). Attention-deficit/hyperactivity disorder medications and long-term risk of cardiovascular diseases. JAMA Psychiatry, 81(2), 178–187. Open source ↗Swedish case-control study; about +4 % cardiovascular risk per year of use, mostly hypertension and arterial disease.
Few or small studies, non-clinical samples, or evidence borrowed from other groups. Treat it as a hypothesis. What these labels mean Mindfulness-based programmes show small-to-moderate effects, with lower-quality evidence than medication or CBT.
Ostinelli et al. 2025
- Meta-analysis Ostinelli EG, et al. (senior author: Cortese S) (2025). Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: a systematic review and component network meta-analysis. The Lancet Psychiatry. Open source ↗Adults only. Short-term symptom benefits for stimulants and atomoxetine; little evidence on quality of life or long-term outcomes.
Strong, replicated evidence — usually meta-analyses or international consensus. Unlikely to change much. What these labels mean Working-memory training improves the trained tasks but not everyday symptoms; consumer neurofeedback shows no benefit and, in one network meta-analysis, a possible unfavourable effect on anxiety.
Melby-Lervåg et al. 2013 +2
- Meta-analysis Melby-Lervåg M, Hulme C (2013). Is working memory training effective? A meta-analytic review. Developmental Psychology, 49(2), 270–291. Open source ↗Gains on trained tasks; little transfer to other skills.
- Meta-analysis Cortese S, Ferrin M, Brandeis D, et al. (2015). Cognitive training for attention-deficit/hyperactivity disorder: meta-analysis of clinical and neuropsychological outcomes from randomized controlled trials. Journal of the American Academy of Child & Adolescent Psychiatry, 54(3), 164–174. Open source ↗Effects on ADHD symptoms shrank when raters were blinded.
- Meta-analysis Yang X, Zhang L, Yu J, Wang M (2025). Short-term and long-term effect of non-pharmacotherapy for adults with ADHD: a systematic review and network meta-analysis. Frontiers in Psychiatry, 16, 1516878. Open source ↗37 RCTs, 2,289 adults; certainty of evidence low to very low; neurofeedback, working-memory training, tai chi and vitamins showed no benefit.
Promising and growing, but incomplete: several consistent studies, often small or without a meta-analysis. Could change. What these labels mean Among CBT components, organisational strategies are the ones most associated with treatment response.
BMJ Mental Health 2024 2024
- Meta-analysis See original article (network meta-analysis) (2024). Components of cognitive–behavioural therapy for mitigating core symptoms in attention-deficit hyperactivity disorder: a systematic review and network meta-analysis. BMJ Mental Health, 27, e301303. Open source ↗43 trials, 3,817 participants; organisational strategies were the component most associated with treatment response.
What these labels mean
What else could explain this
Before starting or changing a treatment, a clinician looks at:
- Heart and blood pressure history, in you and your family
- Anxiety, depression, bipolar disorder, substance use — they change the order of priorities
- Sleep, which can mimic or worsen symptoms
- Pregnancy or breastfeeding, now or planned
- What has already been tried, at what dose, for how long
Amorce never recommends a medication, a dose or a change. If a treatment stops working or feels wrong, the person who prescribed it needs to know — soon, not someday.
Go deeper
Why “short term”? Because almost all randomised trials last 6–12 weeks. That is not a sign that treatment stops working; it is a limit of what has been measured. Register studies that follow people for years fill part of the gap, with the caveat that they compare people who chose differently.
Why do psychiatrists often combine both? Medication changes how much pull a task has and how long attention holds; it does not install a system for keys, deadlines and emails. CBT works on the systems. The two address different layers, which is why guidelines mention both.
What we don’t know yet
- What are the effects of treatment over decades, measured in randomised rather than observational studies?
- Who responds to which treatment? There is no reliable way to predict it in advance.
- How much of CBT’s effect holds when therapy stops, and after a year?
Sources 13
- Meta-analysis Cortese S, Adamo N, Del Giovane C, et al. (2018). Comparative efficacy and tolerability of medications for ADHD in children, adolescents, and adults: a systematic review and network meta-analysis. The Lancet Psychiatry, 5(9), 727–738. Open source ↗133 double-blind randomised trials; short-term outcomes (about 12 weeks).
- Meta-analysis Ostinelli EG, et al. (senior author: Cortese S) (2025). Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: a systematic review and component network meta-analysis. The Lancet Psychiatry. Open source ↗Adults only. Short-term symptom benefits for stimulants and atomoxetine; little evidence on quality of life or long-term outcomes.
- Meta-analysis Knouse LE, Teller J, Brooks MA (2017). Meta-analysis of cognitive-behavioral treatments for adult ADHD. Journal of Consulting and Clinical Psychology, 85(7), 737–750. Open source ↗32 studies; moderate effects on symptoms and functioning versus control, smaller on blinded ratings.
- Randomised trial Safren SA, Sprich S, Mimiaga MJ, et al. (2010). Cognitive behavioral therapy vs relaxation with educational support for medication-treated adults with ADHD and persistent symptoms: a randomized controlled trial. JAMA, 304(8), 875–880. Open source ↗86 adults already on medication; 12 weekly sessions.
- Randomised trial Solanto MV, Marks DJ, Wasserstein J, et al. (2010). Efficacy of meta-cognitive therapy for adult ADHD. American Journal of Psychiatry, 167(8), 958–968. Open source ↗88 adults; 12 weekly group sessions on time management, organisation and planning vs supportive therapy.
- Randomised trial Antshel KM, McBride H, Knouse LE (2025). Bridging the gap: digital CBT for adults managing ADHD challenges. Journal of Attention Disorders. Open source ↗154 adults, 8 weeks, compared with a waitlist (which tends to overestimate effects).
- Cohort / register study Li L, Zhu N, Zhang L, et al. (2024). ADHD pharmacotherapy and mortality in individuals with ADHD. JAMA, 331(10), 850–860. Open source ↗Swedish register, ~149,000 people; observational — lower all-cause mortality over two years with treatment, mainly from unnatural causes.
- Cohort / register study Zhang L, Li L, Andell P, et al. (2024). Attention-deficit/hyperactivity disorder medications and long-term risk of cardiovascular diseases. JAMA Psychiatry, 81(2), 178–187. Open source ↗Swedish case-control study; about +4 % cardiovascular risk per year of use, mostly hypertension and arterial disease.
- Meta-analysis Melby-Lervåg M, Hulme C (2013). Is working memory training effective? A meta-analytic review. Developmental Psychology, 49(2), 270–291. Open source ↗Gains on trained tasks; little transfer to other skills.
- Meta-analysis Cortese S, Ferrin M, Brandeis D, et al. (2015). Cognitive training for attention-deficit/hyperactivity disorder: meta-analysis of clinical and neuropsychological outcomes from randomized controlled trials. Journal of the American Academy of Child & Adolescent Psychiatry, 54(3), 164–174. Open source ↗Effects on ADHD symptoms shrank when raters were blinded.
- Clinical guideline National Institute for Health and Care Excellence (2018). Attention deficit hyperactivity disorder: diagnosis and management (NG87), updated 2019. NICE guideline. Open source ↗UK clinical guideline.
- Consensus statement Kooij JJS, Bijlenga D, Salerno L, et al. (2019). Updated European Consensus Statement on diagnosis and treatment of adult ADHD. European Psychiatry, 56, 14–34. Open source ↗Notes the lack of research on sex and gender differences.
- Meta-analysis Xu S, Zhao C, Hu L (2026). The effects of acute and chronic exercise on executive functions and core symptoms in adults with ADHD: a systematic review and meta-analysis. Psychology of Sport and Exercise, 84, 103088. Open source ↗Single sessions: moderate effect on inhibitory control (4 studies, 152 adults). Regular programmes: too few studies to conclude.
Written: 2026-10 · Written from a structured literature review by a non-professional · Not yet reviewed by a clinician